Page last updated: 2024-12-08

3-carbamoyl-2,2,5,5-tetramethyl-1-pyrrolidinyl-n-oxyl

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3-carbamoyl-2,2,5,5-tetramethyl-1-pyrrolidinyl-N-oxyl: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID521152
CHEMBL ID606682
CHEBI ID187889
MeSH IDM0207903

Synonyms (23)

Synonym
1-pyrrolidinyloxy, 3-(aminocarbonyl)-2,2,5,5-tetramethyl-
1-pyrrolidinyloxy, 3-carbamoyl-2,2,5,5-tetramethyl-
3-carbamoyl-proxyl
3-(aminocarbonyl)-2,2,5,5-tetramethyl-1-pyrrolidinyloxy
nsc 152272
3-carbamoyl-2,2,5,5-tetramethyl-1-pyrrolidinyl-n-oxyl
3-carbamoyl-2,2,5,5-tetramethylpyrrolidin-1-yloxy
einecs 224-533-5
CHEMBL606682
3-carbamoyl-2,2,5,5-tetramethyl-1-pyrrolidinoxy
CHEBI:187889
(3-carbamoyl-2,2,5,5-tetramethylpyrrolidin-1-yl)oxidanyl
STK684494
AKOS005258402
n-3-carbamoyl-2,2,5,5-tetramethylpyrrolidin-1-yloxyl
ccris 8499
2,2,5,5-tetramethyl-1-pyrrolidinyloxy-3-carboxamide
2,2,5,5-tetramethylpyrrolidine-1-oxyl-3-carboxamide
pirolid
proxad
W-200372
DTXSID30963159
3-carbamoyl-2,2,5,5-tetramethyl-1-pyrrolidinyloxy

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" On the basis of the observed time-dependent free radical clearance curves, the following important results were obtained: (1) Free radical clearances were able to analyze by the pharmacokinetic method."( In vivo L-band ESR and quantitative pharmacokinetic analysis of stable spin probes in rats and mice.
Nishino, N; Sakurai, H; Yasui, H, 1999
)
0.3

Dosage Studied

ExcerptRelevanceReference
" Nitroxides (10 mM) were added 10 min prior to radiation exposure and full radiation dose-response curves were determined."( Identification of nitroxide radioprotectors.
DeGraff, W; Gamson, J; Hahn, SM; Krishna, CM; Liebmann, J; Mitchell, JB; Samuni, A; Venzon, D; Wilson, L, 1992
)
0.28
"The authors performed a blinded, dose-response study of the effect of different amounts of 3-CP (1, 10, and 100 mg/kg) on infarct size at 24 hours after focal ischemia and reperfusion."( Neuroprotection by the stable nitroxide 3-carbamoyl-proxyl during reperfusion in a rat model of transient focal ischemia.
Hu, G; Lyeth, BG; Mitchell, JB; Watson, JC; Zhao, X, 2003
)
0.32
" The results obtained in this study demonstrate, that EPR is a powerful method to monitor the first steps of diffusion processes and the physicochemical state of coated dosage forms."( Mechanistic analysis of drug release from tablets with membrane controlled drug delivery.
Mäder, K; Metz, H; Strübing, S, 2007
)
0.34
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
aminoxylsRadicals derived from hydroxylamines by removal of the hydrogen atom from the hydroxy group. The synonymous terms nitroxyl radicals and nitroxides erroneously suggest the presence of a nitro group.
pyrrolidinecarboxamide
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID216890Mean surviving fraction of V79 cells following a 1-h exposure to H2O2.1998Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18
Studies of structure-activity relationship of nitroxide free radicals and their precursors as modifiers against oxidative damage.
AID216900Mean surviving fraction of V79 cells following a 12-Gy dose of radiation.1998Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18
Studies of structure-activity relationship of nitroxide free radicals and their precursors as modifiers against oxidative damage.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (47)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's11 (23.40)18.2507
2000's28 (59.57)29.6817
2010's6 (12.77)24.3611
2020's2 (4.26)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.56 (24.57)
Research Supply Index3.89 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (4.17%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other46 (95.83%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]